Turning Point in the Treatment of Mantle Cell Lymphoma

被引：1
作者：
Motokura, Toru [1 ]
机构：
[1] Tottori Univ, Fac Med, Sch Med, Div Clin Lab Med,Dept Pathophysiol & Therapeut Sc, Yonago, Tottori 6838503, Japan
来源：
YONAGO ACTA MEDICA | 2019年 / 62卷 / 01期
关键词：
bendamustine; bortezomib; ibrutinib; lymphoma; mantle-cell; BRUTON TYROSINE KINASE; PROGNOSTIC INDEX MIPI; 15-YEAR FOLLOW-UP; OPEN-LABEL; B-CELL; PROLYMPHOCYTIC LEUKEMIA; 1ST-LINE TREATMENT; DOSE CYTARABINE; P53; MUTATIONS; PHASE-II;
D O I：
10.33160/yam.2019.03.001
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Mantle cell lymphoma (MCL) is an incurable type of B-cell lymphoma. It is typically composed of small-to-medium-sized cleaved lymphoid cells with cyclin D1 protein expression due to the chromosomal translocation t(11;14)(q13;q32). Even with the development of rituximab, an anti-CD20 antibody drug, the long-term outcome of patients with MCL has not improved. Recently, new agents have been used in clinical settings, and the outcome of patients with MCL is expected to improve. The treatment of MCL may be at a turning point from intensive chemotherapy to chemotherapy-free treatment. In this study, a recent progress in the diagnosis and treatment of MCL is reviewed.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 49 条
  • [1] A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
    Armand, Philippe
    Redd, Robert
    Bsat, Jad
    Mayuram, Sangeetha
    Giardino, Angela
    Fisher, David C.
    LaCasce, Ann S.
    Jacobson, Caron
    Davids, Matthew S.
    Brown, Jennifer R.
    Weng, Li
    Wilkins, Jennifer
    Faham, Malek
    Freedman, Arnold S.
    Joyce, Robin
    Jacobsen, Eric D.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (01) : 89 - 95
  • [2] MANTLE CELL LYMPHOMA - A PROPOSAL FOR UNIFICATION OF MORPHOLOGICAL, IMMUNOLOGICAL, AND MOLECULAR-DATA
    BANKS, PM
    CHAN, J
    CLEARY, ML
    DELSOL, G
    DEWOLFPEETERS, C
    GATTER, K
    GROGAN, TM
    HARRIS, NL
    ISAACSON, PG
    JAFFE, ES
    MASON, D
    PILERI, S
    RALFKIAER, E
    STEIN, H
    WARNKE, RA
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (07) : 637 - 640
  • [3] Chan WC, 1997, BLOOD, V89, P3909
  • [4] Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
    Chang, Betty Y.
    Francesco, Michelle
    De Rooij, Martin F. M.
    Magadala, Padmaja
    Steggerda, Susanne M.
    Huang, Min Mei
    Kuil, Annemieke
    Herman, Sarah E. M.
    Chang, Stella
    Pals, Steven T.
    Wilson, Wyndham
    Wiestner, Adrian
    Spaargaren, Marcel
    Buggy, Joseph J.
    Elias, Laurence
    [J]. BLOOD, 2013, 122 (14) : 2412 - 2424
  • [5] VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study
    Chang, Julie E.
    Carmichael, Lakeesha L.
    Kim, KyungMann
    Peterson, Christopher
    Yang, David T.
    Traynor, Anne M.
    Werndli, Jae E.
    Huie, Michael S.
    McFarland, Thomas A.
    Volk, Michael
    Blank, Jules
    Callander, Natalie S.
    Longo, Walter L.
    Kahl, Brad S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01) : E61 - E67
  • [6] RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106
    Chen, Robert W.
    Li, Hongli
    Bernstein, Steven H.
    Kahwash, Samir
    Rimsza, Lisa M.
    Forman, Stephen J.
    Constine, Louis
    Shea, Thomas C.
    Cashen, Amanda F.
    Blum, Kristie A.
    Fenske, Timothy S.
    Barr, Paul M.
    Phillips, Tycel
    Leblanc, Michael
    Fisher, Richard I.
    Cheson, Bruce D.
    Smith, Sonali M.
    Faham, Malek
    Wilkins, Jennifer
    Leonard, John P.
    Kahl, Brad S.
    Friedberg, Jonathan W.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (05) : 759 - 769
  • [7] Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
    Chihara, Dai
    Cheah, Chan Y.
    Westin, Jason R.
    Fayad, Luis E.
    Rodriguez, Maria A.
    Hagemeister, Fredrick B.
    Pro, Barbara
    McLaughlin, Peter
    Younes, Anas
    Samaniego, Felipe
    Goy, Andre
    Cabanillas, Fernando
    Kantarjian, Hagop
    Kwak, Larry W.
    Wang, Michael L.
    Romaguera, Jorge E.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (01) : 80 - 88
  • [8] Differences in incidence and trends of haematological malignancies in Japan and the United States
    Chihara, Dai
    Ito, Hidemi
    Matsuda, Tomohiro
    Shibata, Akiko
    Katsumi, Akira
    Nakamura, Shigeo
    Tomotaka, Sobue
    Morton, Lindsay M.
    Weisenburger, Dennis D.
    Matsuo, Keitaro
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (04) : 536 - 545
  • [9] p53 mutations and tetraploids under r- and K-selection
    Chikatsu, N
    Nakamura, Y
    Sato, H
    Fujita, T
    Asano, S
    Motokura, T
    [J]. ONCOGENE, 2002, 21 (19) : 3043 - 3049
  • [10] Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
    Cinar, Munevver
    Hamedani, FaridSaei
    Mo, Zhicheng
    Cinar, Bekir
    Amin, Hesham M.
    Alkan, Serhan
    [J]. LEUKEMIA RESEARCH, 2013, 37 (10) : 1271 - 1277
12345